Hello drrakesh,
the newer patent was a mere extension sought by Pfizer. Refer this article for the full context of this.
Judge Allen invalidated the reissue patent for the same reason the Federal Circuit invalidated the original one — “double-patenting.” Pfizer had argued that, as part of the reissue, it had reclassified the patent in a way that made it eligible for a safe harbor that protects patents from invalidation on “double-patenting” grounds. But Judge Allen found that the reissuance process could not be used for that purpose, and the flaw was therefore “not correctable.”
| Subscribe To Our Free Newsletter |
